The Manual of Patent Office Practice designates antibody molecules as a 'special topic' and the Canadian Intellectual Property Office (CIPO) has traditionally treated antibody inventions as special compared with other inventions. However, two recent commissioner's decisions indicate that CIPO is becoming more amenable to treating antibody inventions according to the same rules that apply to other molecules.
The Manual of Patent Office Practice designates antibody molecules as a 'special topic' and the Canadian Intellectual Property Office (CIPO) has traditionally treated antibody inventions as special compared with other inventions. However, two recent Commissioner's decisions indicate that CIPO is becoming more amenable to treating antibody inventions according to the same rules that apply to other molecules.